Compare HCAT & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCAT | BIOA |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.0M | 175.7M |
| IPO Year | 2019 | 2024 |
| Metric | HCAT | BIOA |
|---|---|---|
| Price | $2.72 | $9.22 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 11 | 4 |
| Target Price | $4.30 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 858.1K | 219.3K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $316,063,000.00 | $5,917,000.00 |
| Revenue This Year | $3.23 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.63 | N/A |
| 52 Week Low | $2.02 | $2.88 |
| 52 Week High | $8.91 | $20.37 |
| Indicator | HCAT | BIOA |
|---|---|---|
| Relative Strength Index (RSI) | 49.60 | 64.93 |
| Support Level | $2.02 | $8.46 |
| Resistance Level | $3.03 | $9.62 |
| Average True Range (ATR) | 0.23 | 0.45 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 69.80 | 80.20 |
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.